Lescarden Inc. was founded in 1960 and is based in New York, New York. Lescarden Inc. engages in the research, testing, and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, and cancer applications. The company offers CATRIX Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and burns, as well as for non-healing wounds, such as decubitus ulcers, venous stasis ulcers, and diabetic ulcers. It also provides a line of Catrix-based skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, the company offers nutritional supplements, including BIO-CARTILAGE; and POLY-Nag, a glucosamine polymer for the treatment of osteoarthritis. It also licenses its technologies for commercialization by other companies in Canada, Europe, and Korea. The company sells its products primarily in Europe, the Philippines, and Korea.

Biosite Incorporated company's diagnostic products include its Triage Drugs of Abuse Panel and Triage TOX Drug Screen which are used in hospital settings to test for commonly abused drugs. Its other diagnostic products include tests to detect intestinal parasites, diagnose congestive heart failure, and measure the biomarkers associated with stroke. The Biosite Discovery program is a collaborative research effort to identify protein markers for a variety of ailments. Medical diagnostics firm Inverness Medical Innovations acquired Biosite in 2007.

AVEO Pharmaceuticals' models don't pout, strut, or even turn heads -- unless you're a cancer drug researcher. The biotech firm develops cancer models to uncover how genes mutate into tumors and how tumors progress through additional mutations. AVEO then builds genetic profiles of such tumors and applies them to antibody (protein) drug candidates in preclinical and clinical development to help predict actual human responses. In addition to its own pipeline of potential drugs, AVEO has partnered with other pharmaceutical developers to apply its Human Response Platform to their drug candidates.

IDEXX Laboratories, Inc. company was founded in 1983 and is headquartered in Westbrook, Maine. IDEXX Laboratories, Inc. develops, designs, manufactures, and distributes products for veterinary, and food and water testing markets. It operates in three segments: Companion Animal Group (CAG), Water Quality Products (Water), and Production Animal Segment (PAS). The CAG segment provides point-of-care veterinary diagnostic products, such as instruments and consumables, and rapid assays; and information products and services, and digital radiography systems for veterinarians. This segment also offers commercial veterinary reference laboratory and consulting services to veterinarians in the United States, Canada, Europe, Australia, Japan, and South Africa. The Water segment offers a range of products used in the detection of various microbiological analytes in water to government laboratories, water utilities, and private certified laboratories. The PAS segment provides diagnostic tests and related instrumentation that are used to detect diseases, and to monitor health status in production animals. This segment offers its products primarily to government laboratories, cattle, and poultry and swine producers. IDEXX Laboratories also provides products that test milk for antibiotic residues to dairy producers and processors, as well as to government and food-quality managers. In addition, the company sells point-of-care analyzers and related consumables for use in human medical hospitals and clinics to measure electrolytes, blood gases, acid-base balance, glucose, and ionized calcium, as well as to calculate other parameters, such as base excess and anion gap. It markets and sells its products directly, as well as through independent distributors and other resellers in the Americas, Europe, and the Asia Pacific region.

De Novo Pharmaceuticals, Ltd. was incorporated in 1999 and is based in Cambridge, the United Kingdom. De Novo Pharmaceuticals, Ltd., a drug discovery company, provides computational drug design services. It focuses on small molecule therapeutics. The company provides services to drug discovery customers seeking progress from validated target to novel hits; and to medicinal chemistry groups interested in focused chemical libraries. It offers SkelGen, a chemical structure-generation platform and a suite of software tools for the analysis of structural information on a protein target and the de novo design of molecules to bind into its site, as well as for the hit and lead discovery to the pharmaceutical industry. The company offers its SkelGen for scaffold hopping, virtual high-throughput screening, focused library design, intelligent fragment linking, and low affinity fragment-based design applications. It also provides drug discovery partnerships, such as structure-based drug design, ligand-based drug design, and fragment-based drug design services, as well as focused libraries for medicinal chemistry seeking the design of focused libraries against classes of targets. In addition, the company involves in applying its SkelGen silico drug design platform to design compounds for various targets within the diabetes field.

Senetek PLC (Senetek) is a life sciences company engaged in the development of technologies that target the science of healthy aging. The Company’s business consists of two business segments: dermatological/skincare compounds principally addressing photoaging and other skincare needs (Skincare), and pharmaceuticals, principally those addressing sales of monoclonal antibodies, sexual dysfunction and drug delivery of liquid injectable products (automatic injectors) (Pharmaceutical). The Skincare segment’s products include Pyratine-6, 4HBAP and Kinetin. The Pharmaceutical segment’s products include Invicorp, Reliaject, and diagnostic monoclonal antibodies used in Alzheimer’s and other disease research, which the Company licenses from Research Foundation for Mental Hygiene (RFMH) and sells to Covance Antibody Services Inc. The Company has three wholly owned subsidiaries, Senetek Drug Delivery Technologies Inc. (SSDT), Carme Cosmeceutical Sciences Inc. (CCSI) and Senetek Denmark ApS.

ActivX Biosciences figures that the more you know about protein kinases, the easier it will be to inhibit them. That's the basis of its main product: a platform to profile protein kinases -- enzymes that regulate cell's signaling pathways. Its KiNativ platform has been launched for use by pharmaceutical and biotechnology companies as they develop the kinase inhibitors expected to make drug breakthroughs. The company also has its own pipeline of drug candidates in development, including one in trials for the treatment of Type-2 diabetes. Japanese drugmaker Kyorin Pharmaceutical, with whom ActivX had collaborated since 2002, bought the company in 2005 for $21 million.

DURECT Corporation was founded in 1998 and is based in Cupertino, California. DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for pain, central nervous system, disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulations and delivery platform technologies. The company's products include POSIDUR, a release formulation of bupivacaine under Phase IIb clinical trial, which is used for the treatment of post-surgical pain; and ELADUR, a transdermal bupivacaine patch under Phase IIb clinical trial that provides continuous delivery of bupivacaine for up to three days from a single application, as well as is used for the treatment of pain associated with post-herpetic neuralgia. DURECT Corporation also offers Remoxy, an oral oxycodone gelatin capsule under development with pain therapeutics; and TRANSDUR-Sufentanil, a proprietary transdermal sufentanil patch under development, which provides continuous delivery of sufentanil for a period of up to seven days from a single application. In addition, the company offers CHRONOGESIC (sufentanil), a pain therapy system; and ALZET, the miniature implantable osmotic pumps and accessories for experimental research in mice, rats, and other laboratory animals, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. Further, it designs, develops, and manufactures various biodegradable polymers based on lactide, glycolide, and caprolactone under the LACTEL brand for pharmaceutical and medical device clients for use as raw materials in their products.

Daiichi Sankyo Company, Limited is a Japan-based holding company mainly engaged in the manufacturing and sale of pharmaceuticals. The Company has two business segments. The Pharmaceuticals segment is involved in the research, development, manufacturing and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical making. The Others segment is involved in the real estate leasing, the insurance agency business, as well as the provision of human affairs and accounting services.

PharmaNet, a global, drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug, and medical device industries. PharmaNet offers clinical-development solutions including consulting services, Phase I clinical studies, bioequivalency and pharmacodynamic studies, bioanalytical analyses, and Phase II, III, and IV clinical development programs. In addition, PharmaNet offers technology tools for managing clinical trial data.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.